Valuation: Beta Bionics, Inc.

Market Cap 870M 746M 699M 638M 1.2B 82.95B 1.22B 8.24B 3.21B 41.85B 3.27B 3.2B 139B P/E 2026 *
-9.06x
P/E 2027 * -9x
Enterprise Value 736M 631M 591M 540M 1.02B 70.2B 1.03B 6.97B 2.72B 35.42B 2.77B 2.7B 117B EV / Sales 2026 *
5.5x
EV / Sales 2027 * 4.44x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week-4.37%
Current month+49.14%
1 month+19.67%
3 months+63.27%
6 months+46.97%
Current year-37.20%
1 week 18.47
Extreme 18.4701
20.74
1 month 12.73
Extreme 12.73
20.74
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
24/6/26 Sell

Executive/Senior Manager

-1,258 0.0028%
27/2/26 Sell

Executive/Senior Manager

59,813 0.1359%
27/2/26 Free

Chief Executive Officer

287,944 0.6541%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-4.37%+4.39% - 870M
+0.67%+3.00%+29.37%+15.92% 232B
-0.13%+2.11%+4.71%-17.41% 152B
-1.07%-7.19%-22.17%+22.44% 131B
-4.39%-8.09%-55.07%-11.14% 72.26B
-0.68%-1.35%-16.51%-13.79% 51.57B
+0.05%-1.56%+11.78%+19.49% 52.38B
-1.20%-1.26%+29.71%+27.96% 43.71B
+0.27%+0.03%+40.47%+47.80% 40.72B
+0.23%+10.17%+128.75%+42.76% 33.97B
Average -0.72%+3.68%+15.54%+14.89% 81.09B
Weighted average by Cap. -0.48%+3.71%+9.54%+10.03%

Financials

2026 *2027 *
Net sales 134M 115M 107M 98.19M 185M 12.76B 187M 1.27B 494M 6.44B 503M 492M 21.33B 180M 154M 144M 132M 249M 17.13B 251M 1.7B 662M 8.64B 675M 660M 28.62B
Net income -94.91M -81.32M -76.2M -69.61M -131M -9.05B -133M -899M -350M -4.56B -356M -349M -15.12B -96.44M -82.64M -77.43M -70.73M -133M -9.19B -135M -913M -356M -4.64B -362M -354M -15.36B
Net Debt -134M -115M -107M -98.06M -185M -12.75B -187M -1.27B -493M -6.43B -502M -491M -21.3B -73.32M -62.83M -58.87M -53.78M -101M -6.99B -102M -694M -270M -3.53B -275M -269M -11.68B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
27/08/26 USD 19.14 -1.06% 62,278
25/08/26 USD 19.34 -1.98% 710,957
24/08/26 USD 19.73 +3.57% 864,533
21/08/26 USD 19.05 -2.21% 496,596
20/08/26 USD 19.48 -2.65% 1,933,847
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.34USD
Average target price
20.31USD
Spread / Average Target
+5.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock